Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The acquisition is based on an enterprise value of Rs. 1,660 crore
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
This aims to benefit approximately 4.5 crore families with six crore senior citizens with Rs. 5 lakh free health insurance cover on a family basis
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Subscribe To Our Newsletter & Stay Updated
